Key result
Colchicine administration did not reduce the incidence of atrial fibrillation in the postoperative period of myocardial revascularization surgery compared to control.
Why the study?
Does colchicine prevent atrial fibrillation in patients undergoing elective myocardial revascularization surgery?
RCT (n=140)
Open-label
Computer program
No
Does colchicine prevent atrial fibrillation in patients undergoing elective myocardial revascularization surgery?
In this small open-label RCT, perioperative colchicine did not significantly reduce postoperative atrial fibrillation after myocardial revascularization and was associated with an increased risk of postoperative infection.
Answers are grounded in this paper and cite their sources.
Colchicine does not support routine use to prevent postoperative AF after myocardial revascularization; leaves open efficacy in larger blinded trials.
BACKGROUND: The high prevalence of atrial fibrillation (AF) in the postoperative period of myocardial revascularization surgery increases morbidity and mortality. OBJECTIVE: To assess the efficacy of colchicine to prevent AF in the postoperative period of myocardial revascularization surgery, the impact of AF on hospital length of stay and death, and to identify its risk factors. METHODS: Between May 2012 and November 2013, 140 patients submitted to myocardial revascularization surgery were randomized, 69 to the control group and 71 to the colchicine group. Colchicine was used at the dose of 1 mg orally, twice daily, preoperatively, and of 0.5 mg, twice daily, until hospital discharge. A single dose of 1 mg was administered to those admitted 12 hours or less before surgery. RESULTS: The primary endpoint was AF rate in the postoperative period of myocardial revascularization surgery. Colchicine group patients showed no reduction in AF incidence as compared to control group patients (7.04% versus 13.04%, respectively; p = 0.271). There was no statistically significant difference between the groups regarding death from any cause rate (5.6% versus 10.1%; p = 0,363) and hospital length of stay (14.5 ± 11.5 versus 13.3 ± 9.4 days; p = 0.490). However, colchicine group patients had a higher infection rate (26.8% versus 8.7%; p = 0.007). CONCLUSION: The use of colchicine to prevent AF after myocardial revascularization surgery was not effective in the present study. Brazilian Registry of Clinical Trials number RBR-556dhr.
No takes yet. Share an insight, caveat, or question.
Zarpelon et al. (2016) conducted an RCT in Postoperative atrial fibrillation (n=140). Colchicine vs. Control (no study medication) was evaluated on Atrial fibrillation rate in the postoperative period of myocardial revascularization surgery (RRR 46%, 95% CI -53 to 81, p=0.271). Colchicine administration did not reduce the incidence of atrial fibrillation in the postoperative period of myocardial revascularization surgery compared to control.
Synapse has enriched 10 related papers. Consider them for comparative context: